Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer

1 Dec 2008

Abstract excerpt

BACKGROUND: Enhanced activity of histone deacetylases (HDAC) is associated with more aggressive tumour behaviour and tumour progression in various solid tumours. The over-expression of these proteins and their known functions in malignant neoplasms has led to the development of HDAC inhibitors (HDI) as new anti-neoplastic drugs. However, little is known about HDAC expression in renal cell cancer. METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19099586
DOI: 10.1186/1471-2407-8-381

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancerPMID 19099586Read ↗

The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cellsSemantic proximity Read ↗

Comprehensive analysis of a new prognosis signature based on histone deacetylases in clear cell renal cell carcinoma.Semantic proximity Read ↗

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomySemantic proximity Read ↗

Histone deacetylases and their inhibitors in kidney diseasesSemantic proximity Read ↗

Histone Deacetylase Inhibitors and Epigenetic Modifications as a Novel Strategy in Renal Cell CarcinomaSemantic proximity Read ↗

Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphomaSemantic proximity Read ↗

HDAC inhibitors in kidney development and diseaseSemantic proximity Read ↗

Prognostic role of global DNA‐methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimensSemantic proximity Read ↗

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases <i>In vitro</i> and <i>In vivo</i>Semantic proximity Read ↗

Inhibition of HDAC6 activity in kidney diseases: a new perspectiveSemantic proximity Read ↗

Deregulated expression of HDAC3 in colorectal cancer and its clinical significanceSemantic proximity Read ↗

Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.